Generic Name and Formulations:
Meropenem 500mg, 1g; pwd for IV inj after reconstitution; sodium content 3.92mEq/g.
Indications for MERREM:
Susceptible infections including complicated skin and skin structure infections (SSSI), intraabdominal infections, bacterial meningitis.
Give by IV infusion over 15–30 mins or IV bolus over 3–5 mins (for doses = 1g). SSSI: 500mg every 8hrs. P. aeruginosa associated SSSI, intraabdominal: 1g every 8hrs. Renal impairment: CrCl 26–50mL/min: give recommended dose every 12hrs; CrCl 10–25mL/min: give ½ of recommended dose every 12hrs; CrCl <10mL/min: give ½ of recommended dose every 24hrs.
<3 months: Give by IV infusion over 30 mins. Intraabdominal: <32 weeks gestational age (GA) and <2 weeks postnatal age (PNA): 20mg/kg every 12hrs; <32 weeks GA and ≥2 weeks PNA or ≥32 weeks GA and <2 weeks PNA: 20mg/kg every 8hrs; ≥32 weeks GA and ≥2 weeks PNA: 30mg/kg every 8hrs. ≥3 months: Give by IV infusion over 15–30 mins or IV bolus over 3–5 mins. SSSI: 10mg/kg (>50kg: max 500mg) every 8hrs. P. aeruginosa associated SSSI, intraabdominal: 20mg/kg (>50kg: max 1g) every 8hrs. Meningitis: 40mg/kg (>50kg: max 2g) every 8hrs. >50kg: give max dosing per indication.
Penicillin, cephalosporin, or other β-lactam allergy.
CNS disorders. History of seizures. Renal impairment. Hemodialysis or peritoneal dialysis. Monitor renal, hepatic, and hematopoietic function in long-term use. Evaluate if diarrhea develops. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid: not recommended. May antagonize valproic acid; monitor (consider alternative therapy).
Local reactions, diarrhea, nausea, vomiting, constipation, headache, rash, pruritus, apnea, shock, sepsis, anemia, pain; C. difficile-associated diarrhea, possible neuromotor impairment (eg, seizures, delirium, paresthesias), serious hypersensitivity reactions.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|